To further investigate the protective effect exerted by EBV infection, we treated EBV-positive Raji and EBV-negative Ramos and BL41cells with P(BU)2, sodium butyrate and TGFβ, a combination of agents able to trigger, in the former, EBV immediate early (IE) and early antigen (EA) expression in more than 60% of the population [26]. This evidence concerns the gene TGFB1 and Epstein-Barr virus infection.